Human biomonitoring investigates whether material can be detected in biological samples. It does not test a consumer product, identify a specific source of exposure or establish that a detected particle caused disease. The reviewed studies illustrate both tissue-specific detection and the difficulty of ruling out contamination during clinical collection and laboratory processing.12
What these studies measured
The evidence here includes a clinical pilot involving placenta and meconium and a postmortem case series involving the olfactory bulb. These tissues have different structures, sampling procedures and interpretation. A finding in one tissue cannot be converted into a whole-body burden or generalized to every person. The studies did not trace individual particles from a food package, bottle or garment into the tissue.12
Biomonitoring results also depend on which polymer types the method can recognize and how the biological matrix is removed. A chemical spectrum needs to be distinguished from tissue constituents and from material introduced by sampling equipment. Where negative controls contain the same polymers as the specimens, simply subtracting an assumed background or reporting a positive label without the control information can conceal uncertainty.1
What the studies found
The olfactory-bulb case series reported 8 of 15 decedents with identified particles or fibers and 16 identified synthetic polymer particles and fibers. Its nonfiber objects had 5.5-26.4 µm particle lengths. Identified materials included polypropylene, polyamide or nylon, polyethylene and polyethylene vinyl acetate. A composite fiber was also reported. These findings were based on microFTIR examination of tissue sections and digested filters, with procedural and negative-control filters reported to contain no synthetic polymer particles.2
Scroll horizontally for methods and limits.
| Study and material | Reported result | Method and size context | Limit |
|---|---|---|---|
| Postmortem olfactory bulb specimens2 | 8 of 15 decedents with identified particles or fibers; 16 identified synthetic polymer particles and fibers | MicroFTIR on cryosections and digested filters; 5.5-26.4 µm particle lengths | Small selected case series; no validated recovery test or nanoplastic measurement |
| Placenta and meconium clinical pilot1 | Qualitative positive screening for selected polymers; no general concentration reported here | FTIR; 0.05-0.5 mm reported screening window | Positive negative controls and operating-room materials complicate interpretation |
The clinical pilot detected polyethylene, polypropylene and polyurethane in initial placental screening and polyethylene in an initial meconium sample. Some negative controls were positive as well. After modifying sampling, the investigators found polypropylene in a placental core and polypropylene and polystyrene in meconium, while another placental control contained polystyrene and operating-room fallout contained polyurethane. The detailed pattern matters more than a single headline that tissue “contained plastic.”1
How contamination was evaluated
The clinical investigators examined surgical materials, collection instruments, storage containers and airborne fallout alongside biological specimens. They also used dedicated cleanroom handling and procedural blanks. These checks revealed potential contamination that would have been missed by analyzing only the tissue. They strengthen the paper as a methods lesson, while limiting the extent to which any isolated positive finding can be attributed to material present before clinical collection.1
The olfactory-bulb investigators minimized plastic contact and used blanks throughout processing. They compared spectra with polymer libraries, including weathered plastic reference material. Biological tissue can nonetheless interfere with spectral interpretation. The authors reported that a recovery test was not feasible, and digested tissue was unavailable for some cases. The microscope's resolution did not permit nanoplastic detection. A pore size used during filtration therefore should not be presented as the validated size of every particle the complete method could detect.2
What remains unresolved
Detecting particles in an olfactory bulb does not identify a demonstrated entry route. The authors discussed the olfactory pathway but acknowledged that other routes could not be excluded. A cross-sectional postmortem observation cannot show when an object entered the tissue, how long it remained or whether it contributed to a neurological condition. The occurrence fraction describes the studied decedents; it is not a population prevalence estimate.2
Likewise, screening placenta or meconium is not evidence of a quantified fetal dose or a measured developmental outcome. Contamination controls, the small pilot design and the specified size and polymer window all constrain interpretation. These studies motivate careful measurement, but they cannot identify a safer consumer product or support a health claim about an untested item.1
Results should retain their original measurement basis. A count of objects, a positive chemical identification and a polymer mass concentration are different quantities. No conversion among them is made here. The most useful reading of human biomonitoring pairs the reported finding with its tissue, analytical method, size capability and controls, while keeping source attribution and causal health conclusions open unless directly studied.12
Regulatory status
The supplied regulatory-method documents do not provide a clinical diagnostic cutoff for particles in human tissue. The California framework explicitly distinguishes a monitoring-screening approach from an established human-health threshold; its workshop evidence is not a clinical test standard.3 Drinking-water methods cannot be transferred to tissue or air without matrix-specific validation.4 Read regulatory and analytical scope.
References
- Detection of Microplastic in Human Placenta and Meconium in a Clinical SettingResearch article
- Microplastics in the Olfactory Bulb of the Human BrainResearch article
- Development and application of a health-based framework for informing regulatory action in relation to exposure of microplastic particles in California drinking waterResearch framework
- Analysing microplastics in drinking water: Practical considerationsTechnical report